Concordant expression of TCR Vβ2 by the primary T-ALL sample and engrafted NOD/SCID bone marrow and spleen.

MNCs from primary T-ALL obtained from a patient (A) and from bone marrow and spleen cells (B and C, respectively) harvested from a NOD/SCID mouse preconditioned with cord blood MNCs (10 × 10⁶) and implanted with T-ALL leukemia from the patient (3.3 × 10⁶ cells) were analyzed by flow cytometry for surface expression of TCR Vβ2. In the panels presented, the expression of Vβ2 was determined simultaneously with the expression of the T-ALL marker CD7. The CD7 and Vβ2 mAbs were used as FITC and PE conjugates, respectively. Isotype-matched control mAbs (FITC- or PE-conjugated IgG1) were used to determine appropriate cursor settings for analysis. Percentages of human Vβ2⁺CD7⁺ double-positive cells were 80%, 91%, and 93%, respectively, for samples A, B, and C.